Key result
Rivaroxaban regulatory trial evidence was compromised by the use of a faulty device, potentially putting patients at unnecessary risk.
A BMJ investigation raises concerns about the reliability of rivaroxaban trial data due to the use of a faulty device.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Deborah Cohen (2016) studied this question. Rivaroxaban regulatory trial evidence was compromised by the use of a faulty device, potentially putting patients at unnecessary risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: